View English site

Informacje

Luty 1, 2024 WPD Pharmaceuticals z dumą ogłasza przyznanie Gullapalli Young Investigator Award doktor Angelice Kaczyńskiej

Styczeń 31, 2024 WPD Announces Filing of Annual Financial Statements and Provides Corporate Update

Listopad 1, 2023 WPD Pharmaceuticals Sp. z o. o., received the second tranche of the funds

Wrzesień 8, 2023 WPD Pharmaceuticals Sp. z o. o., received the first tranche of the funds

Sierpień 9, 2023 Signing of Letter of Intent with ACRX Investments Limited

Czerwiec 15, 2023 WPD Pharmaceuticals Announces Closing of Convertible Debenture Private Placement

Maj 1, 2023 Convertible Debenture Offering, Update on Research Project Pipeline and Appointment of Additional Directors

Luty 1, 2023 WPD's Polish Subsidiary Signs Investment Agreement with ACRX Investments Limited

Styczeń 18, 2023 WPD Pharmaceuticals Announces First Adult Patient Dosed in Phase 1B/2 Clinical Trial of Berubicin in The Treatment of Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy

Grudzień 19, 2022 WPD Pharmaceuticals Announces First Two Sites Initiated In Poland In Clinical Trial of Berubicin In The Treatment of Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy (WPD-201)

Grudzień 1, 2022 WPD Pharmaceuticals announces share capital increase in Polish subsidiary

Listopad 25, 2022 WPD Pharmaceuticals Announces First Patient Dosed in Phase 1B/2 Clinical Trial Of Annamycin In The Treatment Of Soft Tissue Sarcoma (STS) Lung Metastases and Provides Corporate Update

Listopad 24, 2022 WPD Pharmaceuticals terminates grant agreement with the NCRD for the POIR.01.01.01-00-2382/20-00 project; resignation from the WPD’s Board of Directors

Listopad 18, 2022 WPD Pharmaceuticals provides corporate update

Maj 16, 2022 WPD Pharmaceuticals Signs Annex to License Agreement with Wake Forest University Health Sciences

Marzec 7, 2022 WPD Pharmaceuticals Signs Consortium Agreement on EuroNanoMed Project

Luty 9, 2022 WPD Pharmaceuticals Announces Proposed Restructuring of Polish Subsidiary

Luty 3, 2022 WPD Pharmaceuticals Announces Appointment of New Director

Styczeń 25, 2022 WPD Pharmaceuticals Enters into Amended and Restated Sublicense Agreement with Moleculin Biotech

Listopad 3, 2022 Zapytanie ofertowe nr 01B/RXnanoBrain/2022

Wrzesień 30, 2022 Zapytanie ofertowe nr 01/RXnanoBRAIN/2022

Lipiec 12, 2022 Zapytanie ofertowe nr 01C/WPD107/2022

Maj 19, 2022 Zapytanie ofertowe nr 01B/WPD107/2022

Kwiecień 8, 2022 Zapytanie ofertowe nr 01/WPD107/2022

Marzec 18, 2022 Zapytanie ofertowe nr 01B/WPD108/2022

Luty 2, 2022 Zapytanie ofertowe nr 01/WPD108/2022

Grudzień 16, 2021 WPD Pharmaceuticals Signs Agreement with NCRD for $6.3M Grant for the Development of Liposomal Annamycin, Intended as a Treatment for AML

Październik 1, 2021 WPD Pharmaceuticals Announces AGSM Results

Wrzesień 2, 2021 WPD Pharmaceuticals Announces AGM September 29; Plans Different Path to Fundraising Through Delisting; WPD Poland Arranges Additional Loans; Communications Consultant in Poland

Lipiec 12, 2021 WPD Pharmaceuticals’ Licensor Receives FDA Fast Track Designation for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme; WPD Poland Arranges Loans

Czerwiec 10, 2021 WPD Pharmaceuticals Invited to Join International Research Consortium

Maj 14, 2021 WPD Pharmaceuticals Provides Update on Audited Financial Statements

Maj 11, 2021 WPD Pharmaceuticals to Receive $6.7 Million Grant for Development of Annamycin Drug Candidate

Maj 5, 2021 WPD Pharmaceuticals Receives Approval for Temporary Management Cease Trade Order For Late Filing of Audited Annual Financial Statements

Kwiecień 29, 2021 WPD Pharmaceuticals Announces Application for a Management Cease Trade Order For Late Filing of Audited Annual Financial Statements

Kwiecień 27, 2021 WPD Pharmaceuticals to Attend the 10th Congress of the Polish Society of Pediatric Oncology and Hematology and Present Assumption of the Phase 1 Study with Berubicin in Pediatric Malignant Gliomas

Kwiecień 13, 2021 WPD Pharmaceuticals and IAG to Host a Joint Webinar, “The Potential of Advanced Imaging to Show the Early Treatment Effects of Berubicin in Brain Cancer”

Kwiecień 6, 2021 WPD Pharmaceuticals Holds Pre-Submission Meeting with the European Medicines Agency and Receives Second Prepayment of C$954,248 From a Total C$7.4 Million Grant for Development of Berubicin

Marzec 30, 2021 WPD Pharmaceuticals Announces Amended Sublicense Agreement with Moleculin Biotech for WP1066, WP1122 and Annamycin Drug Candidates

Marzec 16, 2021 WPD Pharmaceuticals Engages World-Renowned Paediatric Oncology Expert to Support Glioblastoma Programs for WPD101

Luty 24, 2021 WPD Pharmaceuticals Announces Berubicin Supply Agreement for the Upcoming Clinical Trials

Luty 18, 2021 WPD and CNS Pharmaceuticals Announce Positive Opinion of the Polish Central Ethics Committee for the WPD-201 Study and Central IRB Study Level Approval for the CNS-201 Study

Luty 11, 2021 WPD Pharmaceuticals Engages Worldwide Clinical Trials as CRO for Further Support on Berubicin Trials

Luty 9, 2021 WPD Pharmaceuticals Announces US$1.5M Grant Awarded to Polish Research Institute for Independent Clinical Trial of Annamycin

Luty 5, 2021 WPD Pharmaceuticals’ Licensor Announces 100% Survival Achieved in Osteosarcoma Lung Metastases Animal Model of Annamycin Drug

Styczeń 28, 2021 WPD Pharmaceuticals to Participate in the 7th Annual LSX World Congress, a Leading Global Healthcare and Life Sciences Forum

Styczeń 14, 2021 WPD Pharmaceuticals Contracts Clinigen Clinical Supplies Management to Perform QP Certification of Berubicin for the Clinical Trials Authorization

Styczeń 6, 2021 WPD Pharmaceuticals to Collaborate With IAG to Deploy Artificial Intelligence and Quantitative Imaging to Assess the Effects of Berubicin

Październik 26, 2020 WPD Pharmaceuticals Provides Update On Berubicin Drug Candidate in Celebration of National Brain Cancer Day in Canada

Wrzesień 16, 2020 WPD Pharmaceuticals Receives Second Prepayment of $705,000 from Total $7.4 Million Grant for Development of WPD101

Sierpień 17, 2020 WPD Pharmaceuticals Enters into Collaborative Agreement for WP1122, Receives Supply and Appoints New CFO

Lipiec 28, 2020 WPD Pharmaceuticals Provides Update on WPD101, a Drug Candidate Targeting GBM Tumors

Luty 10, 2020 WPD Pharmaceuticals’ WP1066 Drug Candidate Had Breakthrough Discovery

Luty 5, 2020 WPD Pharmaceuticals’ Annamycin Drug Received FDA Approval of Fast Track Designation

Luty 3, 2020 WPD Pharmaceuticals Completed the Acquisition of Two Drug Candidates Bringing Total Development Funding Spent on Drugs Under License to Over USD $100 Million

Styczeń 31, 2020 WPD Pharmaceuticals Completed the Acquisition of Two Pancreatic Cancer Drug Candidates

Styczeń 29, 2020 WPD Pharmaceuticals Receives European Patent for Cancer Targeting Drugs

Styczeń 14, 2020 Westcot Ventures Corp. Announces Name Change to “WPD Pharmaceuticals Inc.”

Styczeń 9, 2020 WPD Pharmaceuticals’ New Discovery for Cancer Targeting Drugs is Granted Patent

Styczeń 8, 2020 WPD Pharmaceuticals Provides 2019 Corporate Year End Review

Grudzień 27, 2019 Westcot Ventures Corp. Announces Listing on the Canadian Securities Exchange

Grudzień 23, 2019 Westcot Ventures Corp. Announces Closing of Transaction of WPD Pharmaceuticals Sp. Z.o.o.

Grudzień 16, 2019 Westcot Ventures Corp. Announces Amending Agreement with WPD Pharmaceuticals Sp. Z.o.o., Voluntary Delisting from the TSX Venture Exchange and Proposed Listing on Canadian Securities Exchange

Listopad 1, 2019 Westcot Announces Results of the Annual General and Special Meeting of Shareholders

Lipiec 17, 2019 Westcot Ventures Corp. Announces Definitive Agreement with WPD Pharmaceuticals Inc

Maj 2, 2019 Westcot Ventures Corp. Announces Letter of Intent for Reverse Takeover with WPD Pharmaceuticals Inc. and Director Appointment

Marzec 31, 2019 WESTCOT ANNOUNCES BOARD AND MANAGEMENT CHANGES; TERMINATION OF SHARE EXCHANGE AGREMENT

Grudzień 21, 2018 WESTCOT ANNOUNCES CHANGE OF AUDITOR

Sierpień 28, 2018 WESTCOT CLOSES PRIVATE PLACEMENTS TO RAISE UP TO $2,764,998.60 AND ENTERS INTO SHARE EXCHANGE AGREEMENT

Lipiec 27, 2018 WESTCOT ANNOUNCES PRIVATE PLACEMENTS TO RAISE UP TO $3,100,000 AND PROVIDES CORPORATE UPDATE

Lipiec 19, 2018 WESTCOT ANNOUNCES AGM RESULTS

Lipiec 10, 2018 WESTCOT PROPOSES 2:1 FORWARD SPLIT

Czerwiec 7, 2018 WESTCOT VENTURES CORP. ANNOUNCES PROPOSED CHANGE OF BUSINESS

Listopad 21, 2017 WESTCOT CLOSES PRIVATE PLACEMENT AND ANNOUNCES MANAGEMENT CHANGES

Październik 18, 2017 WESTCOT ANNOUNCES PRIVATE PLACEMENT

Październik 10, 2017 WESTCOT REPORTS DEBENTURES CONVERSION

Wrzesień 18, 2017 WESTCOT ANNOUNCES CHANGE OF TRADING SYMBOL

Wrzesień 14, 2017 SPARROW ANNOUNCES REINSTATEMENT TO TRADING, CONSOLIDATION, AND NAME CHANGE TO WESTCOT VENTURES CORP.

Sierpień 11, 2017 SPARROW ANNOUNCES APPOINTMENT OF CHIEF FINANCIAL OFFICER

Czerwiec 23, 2017 SPARROW CLOSES FINAL TRANCHE OF SECURED CONVERTIBLE DEBENTURES OFFERING AND APPOINTS DIRECTOR

Marzec 17, 2017 SPARROW CLOSES THIRD TRANCHE OF SECURED CONVERTIBLE DEBENTURES OFFERING

Luty 8, 2017 SPARROW ANNOUNCES REVOCATION OF CEASE TRADE ORDERS

Styczeń 17, 2017 SPARROW CLOSES SECOND TRANCHE OF SECURED CONVERTIBLE DEBENTURES OFFERING

Październik 31, 2016 SPARROW ANNOUNCES NEW DIRECTOR APPOINTMENT

Październik 3, 2016 SPARROW ANNOUNCES FIRST CLOSING OF SECURED CONVERTIBLE DEBENTURES OFFERING AND APPOINTS DIRECTOR

Sierpień 18, 2016 SPARROW ANNOUNCES PARTIAL REVOCATION OF CEASE TRADE ORDER

Sierpień 24, 2015 SPARROW ANNOUNCES RESIGNATION OF DIRECTOR

Czerwiec 25, 2015 SPARROW ANNOUNCES RESIGNATION OF CFO

Czerwiec 17, 2014 SPARROW ANNOUNCES GRANT OF OPTIONS

Czerwiec 16, 2014 TRANSFER OF LISTING TO NEX

Czerwiec 4, 2014 Sparrow Announces Unsecured Loan

Maj 1, 2013 Sparrow Adopts Advance Notice Policy for Future Shareholder Meetings

Maj 1, 2013 Sparrow Adopts Advance Notice Policy for Future Shareholder Meetings

Maj 1, 2013 Sparrow Adopts Advance Notice Policy for Future Shareholder Meetings

Styczeń 20, 2012 SPARRROW ANNOUNCES NEW APPOINTMENT TO ITS MANAGEMENT TEAM

Styczeń 20, 2012 SPARRROW ANNOUNCES NEW APPOINTMENT TO ITS MANAGEMENT TEAM

Czerwiec 27, 2011 SPARROW ADDRESSES POSTAL STRIKE EFFECTS ON AGM

Maj 27, 2011 SPARROW ANNOUNCES GRANT OF OPTIONS

Kwiecień 13, 2011 Sparrow Announces Director Resignation

Październik 7, 2010 SPARROW VENTURES ANNOUNCES GRANT OF OPTIONS

Październik 1, 2010 SPARROW APPOINTS RODNEY STEVENS AS SECRETARY

Sierpień 31, 2010 SPARROW VENTURES ANNOUNCES GRANT OF OPTIONS

Sierpień 26, 2010 SPARROW VENTURES CORP. COMPLETES QUALIFYING TRANSACTION

Sierpień 16, 2010 SPARROW VENTURES CORP. FILES FILING STATEMENT REGARDING QUALIFYING TRANSACTION WITH FULL METAL MINERALS LTD.

Maj 26, 2010 SPARROW VENTURES CORP. TERMINATES QUALIFYING TRANSACTION WITH NETWORK ENTERTAINMENT AND ANNOUNCES LETTER AGREEMENT WITH FULL METAL MINERALS FOR EXECUTION OF QUALIFYING TRANSACTION

Maj 3, 2010 SPARROW VENTURES CORP. ANNOUNCES EXTENSION TO LETTER OF INTENT WITH NETWORK ENTERTAINMENT

Kwiecień 16, 2010 SPARROW VENTURES CORP. ANNOUNCES EXTENSION TO LETTER OF INTENT WITH NETWORK ENTERTAINMENT

Luty 22, 2010 SPARROW VENTURES CORP. ANNOUNCES EXTENSION TO LETTER OF INTENT WITH NETWORK ENTERTAINMENT

Luty 17, 2010 SPARROW VENTURES CORP. ANNOUNCES PROPOSED QUALIFYING TRANSACTION

Grudzień 30, 2009 SPARROW CLOSES FINANCING

Listopad 10, 2009 SPARROW ANNOUNCES FINANCING

Październik 8, 2009 SPARROW VENTURES CORP. TERMINATES LETTER OF INTENT AND QUALIFYING TRANSACTION WITH JSX ENERGY (THAILAND) LIMITED

Marzec 19, 2009 SPARROW VENTURES CORP. ANNOUNCES PROPOSED QUALIFYING TRANSACTION

Maj 21, 2008 INITIAL PUBLIC OFFERING COMPLETED